摘要
干扰素（Ｉｎｔｅｒｆｅｒｏｎ，ＩＦＮ）是由机体受病毒感染后所产生的细胞因子，具有广泛的抗病毒、抗增殖、抗肿瘤和免疫调节活性，是目前唯一被公认的治疗病毒性肝炎的有效药物，已广泛应用于慢性乙型肝炎和急慢性丙型肝炎患者，经４个月以上的疗程能使４０％～６０％...
出处
《广东医学院学报》
1998年第1期64-67,共4页
Journal of Guangdong Medical College
参考文献20
-
1Fattovich G,Giustina G,Favarato S,et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon.J Hepatol,1996,24(1):38.
-
2Andrione P,Cursaro C,Gramenzi A.et al.Indomethacin enhances serum 2'5'-oligoademylate synthetase in patients with hepatitis B and C virus chronic active hepatitis, J Hepatol,1994,21(6):984.
-
3Itoh H,Nakata H,Yokoya Y,et al. Efficacy and side effects of intermittent recombinant interferon-alpha-2a in chronic aggressive hepatitis C:with or without initial daily administration. J Gastroenterol Hepatol,1996,11(8):718.
-
4Dourakis SP,Deutsch M, Hadziyannis SJ, et al. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol,1996,25(6):972.
-
5Jacquot C,Caudwell V,Belenfant X. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: Evidence for a synergistic hematologic toxicity.Am J Med,1996,101(2):235.
-
6Perrillo R,Tamburro C, Regenstein F,et al. Low-dose,titratahle interferon alph in decompensated liver disease caused by chronic infection with hepatitis B virus.Gastroenterology,1995,109(3):908.
-
7Todros L,Saracco G,Durazzo M.et al. Efficacy and safety of interferon alph therapy in chronic hepatitis C with autoantibodies to liver kidney microsomes. Hepatology,1995,22:1374.
-
8Janssen HL,Brouwer JT,Van Der Mast RC.et al.Suicide associated with alph-interferon therapy for chronic viral hepatitis, J Hepato1,1994,21 (2):241.
-
9Shakil AO,Di Bisceglie AM,Hoofnagle JH, Seizures during alpha interferon therapy. J Hepatol,1996,24(1):48.
-
10Valentine AD,Meyers CA,Talpaz M. Treatment of neurot-oxic side effects of interferon-alpha with naltrexone,Cancer Invest.1995,13:561.
二级引证文献7
-
1唐红梅,陈钫,王新华,霍翠华,王景华.聚乙二醇干扰素致患儿不良反应的特点及护理[J].护理学杂志,2010,25(5):35-36. 被引量：1
-
2徐宁,王洪.干扰素抗肝炎病毒治疗引起甲状腺功能改变的治疗及护理[J].护理研究（下旬版）,2010,24(6):1668-1669. 被引量：3
-
3张玉霞,吴秀琳,车秀英.干扰素不良反应的临床观察及护理对策[J].全科护理,2011,9(18):1636-1637. 被引量：3
-
4吴宝英.丙型肝炎干扰素治疗并发粒细胞减少的护理效果探讨[J].中国基层医药,2012,19(15):2386-2387. 被引量：2
-
5商建红.干扰素治疗慢性乙型肝炎副反应的护理进展[J].当代护士（中旬刊）,2013,20(5):14-15. 被引量：2
-
6张了云,王利平,甘可兰.回顾我院注射用重组人干扰素α2b致罕见变态反应1例并2012至2015年47例不良反应报告分析[J].中国药事,2016,30(6):635-638. 被引量：2
-
7王静.聚乙二醇干扰素治疗慢性丙型肝炎的不良反应及护理体会[J].黑龙江医药,2014,27(1):206-208. 被引量：2
-
1周方钧,赵林阳,高焱莎.心肌炎后扩张型心肌病[J].吉林医学,1993,14(1):3-4.
-
2晋海玲.病毒性心肌炎30例临床分析[J].南京铁道医学院学报,1996,15(4):291-291.
-
3杨英珍.病毒性心肌炎进展（二）[J].中国中西医结合杂志,1995,15(9):557-561. 被引量：33
-
4徐大华,唐晓燕,陆光斌.肺炎性假瘤26例临床分析[J].华西医科大学学报,1997,28(3):347-348. 被引量：1
-
5艾伯维宣布维建乐~联合易奇瑞~丙肝治疗方案获得CFDA批准[J].临床合理用药杂志,2018,11(11):176-176.
-
6马素云,裴志刚.中西医结合治疗丙型肝炎46例[J].中国中西医结合杂志,1996,16(9):558-558. 被引量：5
-
7李莉,朱传琳.干扰素治疗病毒性肝炎近期疗效观察[J].中华实验和临床病毒学杂志,1995,9(4):380-380.
-
8付金玉.HCV-cAg与HCV-Ab联合检测对丙型肝炎的诊断价值[J].河南医学研究,2018,27(4):684-685. 被引量：4
-
9徐姗,苏丹.临床药师参与1例滤泡性淋巴瘤合并丙型肝炎患者免疫化疗方案制订的病例分析[J].中国药房,2018,29(9):1267-1270. 被引量：2
-
10黄凤霞,姚珊,张福.丙型肝炎与胆囊胆道感染[J].长春中医学院学报,1994,10(A02):28-28.
